Ecliptasaponin ACAS# 78285-90-2 |
- Ecliptasaponin D
Catalog No.:BCN2760
CAS No.:206756-04-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 78285-90-2 | SDF | Download SDF |
| PubChem ID | 476537 | Appearance | White powder |
| Formula | C36H58O9 | M.Wt | 634.9 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | Ecliptasaponin A | ||
| Solubility | Soluble in methan | ||
| Chemical Name | (4aR,5R,6aR,6aS,6bR,8aR,10S,12aR,14bS)-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid | ||
| SMILES | CC1(CCC2(C(C1)C3=CCC4C5(CCC(C(C5CCC4(C3(CC2O)C)C)(C)C)OC6C(C(C(C(O6)CO)O)O)O)C)C(=O)O)C | ||
| Standard InChIKey | WYDPEADEZMZKNM-ZBKPBKBGSA-N | ||
| Standard InChI | InChI=1S/C36H58O9/c1-31(2)14-15-36(30(42)43)20(16-31)19-8-9-23-33(5)12-11-25(45-29-28(41)27(40)26(39)21(18-37)44-29)32(3,4)22(33)10-13-34(23,6)35(19,7)17-24(36)38/h8,20-29,37-41H,9-18H2,1-7H3,(H,42,43)/t20-,21+,22-,23+,24+,25-,26+,27-,28+,29-,33-,34+,35+,36+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ecliptasaponin A has protective effects against the pulmonary fibrosis induced by bleomycin via reducing the oxidative stress, lung tissue inflammation, and the subsequent epithelial-mesenchymal transition. |
| Targets | TGF-β/Smad | COX | MMP(e.g.TIMP) | α-SMA | SOD |
| In vivo | Preventive effects of Ecliptae Herba extract and its component, ecliptasaponin A, on bleomycin-induced pulmonary fibrosis in mice.[Pubmed: 26385580 ]J Ethnopharmacol. 2015 Dec 4;175:172-80.Ecliptae Herba, a nourishing traditional Chinese medicine, is also a folk medicine for the treatment of lung diseases.
To investigate the anti-fibrosis effects and the underlying mechanism of the extract of Ecliptae Herba and its potential active components.
|
| Structure Identification | ScientificWorldJournal. 2015;2015:980890.Qualitative and quantitative analysis of Eclipta prostrata L. by LC/MS.[Pubmed: 25667939 ]Eclipta prostrata L. is one of the Chinese medicinal tonics which are usually used for treating loose teeth, dizziness, tinnitus, hemoptysis, hematuria, and uterine bleeding. However, quality control of this herbal medicine has been not satisfactory. |
Ecliptasaponin A Dilution Calculator
Ecliptasaponin A Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5751 mL | 7.8753 mL | 15.7505 mL | 31.501 mL | 39.3763 mL |
| 5 mM | 0.315 mL | 1.5751 mL | 3.1501 mL | 6.3002 mL | 7.8753 mL |
| 10 mM | 0.1575 mL | 0.7875 mL | 1.5751 mL | 3.1501 mL | 3.9376 mL |
| 50 mM | 0.0315 mL | 0.1575 mL | 0.315 mL | 0.63 mL | 0.7875 mL |
| 100 mM | 0.0158 mL | 0.0788 mL | 0.1575 mL | 0.315 mL | 0.3938 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Nepafenac
Catalog No.:BCC1258
CAS No.:78281-72-8
- Hydroxysafflor yellow A
Catalog No.:BCN1049
CAS No.:78281-02-4
- [Orn5]-URP
Catalog No.:BCC5985
CAS No.:782485-03-4
- Paroxetine HCl
Catalog No.:BCC5054
CAS No.:78246-49-8
- 20(S)-Ginsenoside Rh2
Catalog No.:BCN1070
CAS No.:78214-33-2
- Nirtetralin
Catalog No.:BCN3755
CAS No.:78185-63-4
- YM155
Catalog No.:BCC2251
CAS No.:781661-94-7
- 4-Hydroxyisoleucine
Catalog No.:BCN1211
CAS No.:781658-23-9
- CDPPB
Catalog No.:BCC7610
CAS No.:781652-57-1
- MK-0974
Catalog No.:BCC1756
CAS No.:781649-09-0
- DAMGO
Catalog No.:BCC6958
CAS No.:78123-71-4
- Okadaic acid
Catalog No.:BCC2464
CAS No.:78111-17-8
- 7-Ethylcamptothecin
Catalog No.:BCN2480
CAS No.:78287-27-1
- H-D-1-Nal-OH
Catalog No.:BCC3281
CAS No.:78306-92-0
- MRK 016
Catalog No.:BCC6070
CAS No.:783331-24-8
- MLN120B
Catalog No.:BCC1772
CAS No.:783348-36-7
- PCI-24781 (CRA-024781)
Catalog No.:BCC2155
CAS No.:783355-60-2
- Nocamycin I
Catalog No.:BCN1845
CAS No.:78339-49-8
- Pyranojacareubin
Catalog No.:BCN7429
CAS No.:78343-62-1
- MY-5445
Catalog No.:BCC6645
CAS No.:78351-75-4
- 1,7-Dihydroxy-2,3-dimethoxyxanthone
Catalog No.:BCN7523
CAS No.:78405-33-1
- Milrinone
Catalog No.:BCC4374
CAS No.:78415-72-2
- Trequinsin hydrochloride
Catalog No.:BCC7333
CAS No.:78416-81-6
- 5,7,3'-Trihydroxy-6,4',5'-trimethoxyflavone
Catalog No.:BCN1353
CAS No.:78417-26-2
Qualitative and quantitative analysis of Eclipta prostrata L. by LC/MS.[Pubmed:25667939]
ScientificWorldJournal. 2015;2015:980890.
Eclipta prostrata L. is one of the Chinese medicinal tonics which are usually used for treating loose teeth, dizziness, tinnitus, hemoptysis, hematuria, and uterine bleeding. However, quality control of this herbal medicine has been not satisfactory. This study reported its qualitative and quantitative analyses based on LC/MS method. UHPLC-DAD-Q-TOF-MS fingerprinting and MS fragmentation cleavage pathway were investigated for qualitative analysis. Furthermore, a method for simultaneous quantitative determination of nine compounds, luteolin 7-O-beta-D-glucopyranoside, ecliptasaponin C, luteolin, eclalbasaponin IV, apigenin, Ecliptasaponin A, echinocystic acid 28-O-beta-D-glucopyranoside, echinocystic acid, and 3-oxo-16alpha-hydroxy-olean-12-en-28-oic acid in E. prostrata, was established. The method was validated for samples of E. prostrata from different habitats. The results showed good linear correlation, precision, accuracy, and repeatability that could be used for contents determination of the nine compounds in E. prostrata from different habitats.
Preventive effects of Ecliptae Herba extract and its component, ecliptasaponin A, on bleomycin-induced pulmonary fibrosis in mice.[Pubmed:26385580]
J Ethnopharmacol. 2015 Dec 4;175:172-80.
ETHNOPHARMACOLOGICAL RELEVANCE: Ecliptae Herba, a nourishing traditional Chinese medicine, is also a folk medicine for the treatment of lung diseases. AIM OF THE STUDY: To investigate the anti-fibrosis effects and the underlying mechanism of the extract of Ecliptae Herba and its potential active components. MATERIALS AND METHODS: The resulting extract (EXT) was prepared from the 80% ethanol extract of Ecliptae Herba. After intratracheally administrated with bleomycin (BLM, 5mg/kg), mice were orally treated with EXT at 2.5, 1.25, 0.625 g/kg and eclipta saponin A (ESA) at 80 mg/kg once daily for 28 day. The bodyweight, survival rate, pathological changes of lung and levels of hydroxyproline (HYP) were used to evaluate the anti-fibrotic effects. The malonaldehyde (MDA), superoxidae dismutase (SOD) activity, and the protein expressions of matrix metalloproteinase (MMP)-2, 9, tissue inhibitor of metalloproteinase-1 (TIMP-1), cyclooxygenase-2 (COX-2), alpha-smooth muscle actin (alpha-SMA) and transforming growth factor-beta1 (TGF-beta1) in lung tissue were analyzed by kits or western blot. RESULTS: Compared with BLM group, EXT administration could significantly ameliorated the pathological changes of lung, decreased the HYP content, enhanced the SOD activity, and reduced the MDA content of lung tissues. In mechanism, EXT significantly alleviated the levels of COX-2, TGF-beta1, MMP-2 and alpha-SMA, as well as elevated the ratio value of MMP-9/TIMP-1. Additionally, the anti-fibrosis effects of ESA, a large amount of saponins isolated from Eclipta prostrata , was also evaluated by the BLM-induced model. The results showed that ESA could block BLM-induced histological changes of lung tissue and decrease the high levels of TGF-beta1 and alpha-SMA. CONCLUSIONS: Ecliptae Herba has protective effects against the pulmonary fibrosis induced by BLM via reducing the oxidative stress, lung tissue inflammation, and the subsequent epithelial-mesenchymal transition. The active chemical constituents may be involved with triterpenoid saponins, such as ESA.
